0000899243-20-018812.txt : 20200709
0000899243-20-018812.hdr.sgml : 20200709
20200709160030
ACCESSION NUMBER: 0000899243-20-018812
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200707
FILED AS OF DATE: 20200709
DATE AS OF CHANGE: 20200709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novak Rodger
CENTRAL INDEX KEY: 0001682017
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 201020524
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-07
0
0001674416
CRISPR Therapeutics AG
CRSP
0001682017
Novak Rodger
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE
MA
02139
1
1
0
0
President
Common Shares
2020-07-07
4
M
0
5586
1.81
A
653593
D
Common Shares
2020-07-07
4
M
0
19414
14.00
A
673007
D
Common Shares
2020-07-07
4
S
0
25000
90.00
D
648007
D
Stock Option (Right to Buy)
1.81
2020-07-07
4
M
0
5586
0.00
D
2025-09-10
Common Shares
5586
0
D
Stock Option (Right to Buy)
14.00
2020-07-07
4
M
0
19414
0.00
D
2026-10-18
Common Shares
19414
140826
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vesting in 31 equal monthly installments thereafter.
This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.
/s/ Michael Esposito, attorney-in-fact
2020-07-09